- Home
- LSB vs MRSN Comparison
LSB vs MRSN Comparison
Compare LSB & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- MRSN
- Stock Information
- Founded
- LSB 2002
- MRSN 2001
- Country
- LSB China
- MRSN United States
- Employees
- LSB N/A
- MRSN N/A
- Industry
- LSB
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- MRSN Health Care
- Exchange
- LSB NYSE
- MRSN Nasdaq
- Market Cap
- LSB 32.2M
- MRSN 36.4M
- IPO Year
- LSB N/A
- MRSN 2017
- Fundamental
- Price
- LSB $1.38
- MRSN $0.35
- Analyst Decision
- LSB
- MRSN Buy
- Analyst Count
- LSB 0
- MRSN 3
- Target Price
- LSB N/A
- MRSN $4.00
- AVG Volume (30 Days)
- LSB 34.3K
- MRSN 3.1M
- Earning Date
- LSB 12-19-2024
- MRSN 05-08-2025
- Dividend Yield
- LSB N/A
- MRSN N/A
- EPS Growth
- LSB N/A
- MRSN N/A
- EPS
- LSB N/A
- MRSN N/A
- Revenue
- LSB $79,415,311.00
- MRSN $40,497,000.00
- Revenue This Year
- LSB $39.33
- MRSN N/A
- Revenue Next Year
- LSB $75.61
- MRSN N/A
- P/E Ratio
- LSB N/A
- MRSN N/A
- Revenue Growth
- LSB N/A
- MRSN 9.88
- 52 Week Low
- LSB $1.50
- MRSN $0.26
- 52 Week High
- LSB $11.20
- MRSN $3.83
- Technical
- Relative Strength Index (RSI)
- LSB 28.40
- MRSN 44.90
- Support Level
- LSB $1.50
- MRSN $0.31
- Resistance Level
- LSB $1.79
- MRSN $0.40
- Average True Range (ATR)
- LSB 0.23
- MRSN 0.05
- MACD
- LSB -0.08
- MRSN 0.01
- Stochastic Oscillator
- LSB 5.80
- MRSN 68.09
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.